Surgical Treatment of Cerebral Hydatidosis

Duishanbai, Sailike; Wen, Hao

doi:10.1007/978-3-642-54359-3_15

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MBZ is recommended for the chemotherapy of non-surgical cases and as a supplementary treatment prior to and post-surgery of EIHs; such as alveolar and cystic hydatid disease. MBZ 40-50 mg/kg per day for 3-6 months have demonstrated efficacy [2,8,9]. The prolonged, highdose therapy used in the treatment of EIHs has been associated with alopecia, hepatocellular injury and bone marrow suppression [6,10].…”

Section: Introductionmentioning

confidence: 99%

Formulation, Optimization and In Vitro Evaluation of Solubility Enhanced Fast Disintegrating Tablets of Mebendazole

Assefa¹,

Belete²,

Joseph³

2018

J Bioequiv Availab

View full text Add to dashboard Cite

Mebendazole (MBZ) is used for the treatment of different intestinal helminthic infections (IHIs) and extraintestinal helminthic infections (EIHs). Due to its poor aqueous solubility and high first pass metabolism, MBZ has low bioavailability that can affect the therapeutic efficacy of the drug for EIHs. The aim of the present study is to develop solubility enhanced rapidly disintegrating tablets of MBZ with a simple and industrially feasible manufacturing process.

show abstract